TOPICAL FORMULATIONS
The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes an active agent, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.
1 . A topical formulation comprising:
(i) at least one active agent,
(ii) a first compound, and
(iii) a second compound,
wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.
2 . The topical formulation of claim 1 , wherein the first compound comprises sodium lauryl sulfoacetate and the second compound comprises isopropyl myristate.
3 . The topical formulation of claim 1 , wherein the first compound comprises sodium lauryl sulfoacetate and the second compound comprises methyl laurate.
4 . The topical formulation of claim 1 , wherein the first compound comprises isopropyl myristate and the second compound comprises N-lauryl sarcosine.
5 . The topical formulation of claim 1 , wherein the first compound comprises glyceryl monooleate and the second compound comprises methyl laurate.
6 . The topical formulation of claim 1 , wherein the first compound comprises N-lauroyl sarcosine and the second compound comprises oleic acid.
7 . The topical formulation of claim 1 , wherein the first compound comprises sodium octyl sulfate and the second compound comprises oleic acid.
8 . The topical formulation of claim 1 , wherein the first compound comprises glyceryl oleate and the second compound comprises sodium octyl sulfate.
9 . The topical formulation of claim 1 , further comprising a biologically acceptable excipient.
10 . The topical formulation of claim 1 , wherein the total concentration of the first compound and the second compound is up to about 50 wt. %, 40 wt. %, 35 wt. %, 30 wt. %, 25 wt. %, 20 wt. %, 15 wt. %, 10 wt. %, 7.5 wt. % or 5 wt. %, per unit volume of the formulation.
11 . The topical formulation of claim 1 , wherein the total concentration of the first compound and the second compound is in the range of from about 2 wt. % to about 5 wt. %, per unit volume of the formulation.
12 . The topical formulation of claim 1 , wherein the total concentration of the first compound and the second compound is in the range of from about 2 wt. % to about 4 wt. %, per unit volume of the formulation.
13 . The topical formulation of claim 1 , wherein the weight ratio of the first compound to the second compound is in the range of from about 1:9 to about 9:1.
14 . The topical formulation of claim 1 , wherein the weight ratio of the first compound to the second compound is in the range of from about 1:4 to about 4:1.
15 . The topical formulation of claim 1 , wherein the weight ratio of the first compound to the second compound is in the range of from about 1:3 to about 3:1.
16 . The topical formulation of claim 1 , wherein the weight ratio of the first compound to the second compound is in the range of from about 1:2 to about 2:1.
17 . The topical formulation of claim 1 , wherein the weight ratio of the first compound to the second compound is about 1:1.